Call for further study on meningococcal vaccine

Epidemiologist Dr Mahomed Patel said that an analysis of historical patterns of meningococcal incidence should also be examined to better understand, and further prevent, the bacterial infection.

"The meningococcal vaccine has been effective since its introduction in 2003, but the disease incidence rate is still higher than 20 years ago. We could do better," Dr Patel said.

In a paper published in the Medical Journal of Australia, Dr Patel argues that although the vaccine is an important part of controlling meningococcal infections, its impact on the body's natural bacterial balance has not been adequately studied.

He identifies examples where the vaccines against two other bacterial infections – pneumococci and Haemophilus influenzae type b – were followed by an increase in the bacterial strains not covered by the vaccine. "It's not unlikely that this may occur with the meningococcal vaccines, so the more we know about the broader role of the meningococcus bacteria in the throat, the better," Dr Patel said.

About 10 percent of the population carries the meningococcal bacteria and less than one per cent of these people develop disease. The routine vaccination for one type of meningococcus bacteria, Type C, was introduced Australia-wide in 2003, costing $41 million in its first year.

Before the vaccine was introduced, about 1 person per 100,000 in Australia developed meningococcal disease due to Type C bacteria each year. A new vaccine for a different strain, Type B, has been introduced in New Zealand and is likely to be used here in the near future.

Dr Patel argues that the pattern of meningococcal disease over time should also inform control options. In his paper he found that in periods of upheaval – the World Wars and the Depression – epidemics of meningococcal disease occurred around the world. Many cases also occurred in the 1950s at the time of mass migrations from Europe to Australia, New Zealand and North America.

The only epidemics in Australia after this period were among poverty-stricken Indigenous communities in central Australia in 1972 and again in 1987. In the 1960 to 1970s, incidence across Australia fell, but rose again since the late 1980s until the introduction of the vaccine.

"This information is useful for understanding ongoing trends. Combined with knowledge of the effect of the vaccine on the bacteria, this could be powerful information for more effectively reducing infections."

Source: Research Australia

Related stories:

Tool creates personalized catch-up immunization schedules for missed childhood vaccinations
A new downloadable software tool will help pediatricians, parents and other health care professionals determine how to adjust complex childhood immunization schedules when one or more vaccine doses aren’t received at the proper time.
Steroids provide no survival benefit for children with bacterial meningitis
Corticosteroids given to children who are hospitalized for bacterial meningitis do not provide a benefit in survival or in reduced hospital stays, according to a large multicenter study by pediatric researchers. This finding stands in contrast to previous studies in hospitalized adults, for which corticosteroids dramatically reduced mortality.
Newer meningitis vaccine appears safe and effective for infants
A vaccine not yet licensed in the United States produces immunity against four strains of meningococcal disease and is well tolerated when administered to infants, according to a study in the January 9/16 issue of JAMA.
FDA expands meningitis vaccine approval
The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.
FDA expands meningitis vaccine age range
The U.S. Food and Drug Administration has expanded the approved age range for Menactra, a bacterial meningitis vaccine.
12 cases of brain disease after vaccines
The U.S. Food and Drug Administration said 12 cases of a neurological disorder have been reported following the application of a meningococcal vaccine.
Secondhand smoke increases hospital admissions for all types of infectious diseases
Children exposed to second hand tobacco smoke are more likely to get severe infectious diseases and have to be admitted to hospital, finds research published online ahead of print in Tobacco Control.
New discovery on role of vital protein that fights meningitis
A University of Leicester researcher has discovered how a protein in the blood – linked to defence against meningitis - plays a more vital role than previously understood in the body’s immune defence system.

News discussion:

Medicine & Health news